Opposing actions of Arx and Pax4 in endocrine pancreas development. by Collombat, P. et al.
Opposing actions of Arx and Pax4
in endocrine pancreas development
Patrick Collombat,1 Ahmed Mansouri,1 Jacob Hecksher-Sørensen,2 Palle Serup,2 Jens Krull,1
Gerard Gradwohl,3 and Peter Gruss1,4
1Department of Molecular Cell Biology, Max-Planck Institute for Biophysical Chemistry, D-37077 Göttingen, Germany;
2Department of Developmental Biology, Hagedorn Research Institute, DK-2820 Gentofte, Denmark; 3Institut National de la
Sante et de la Recherche Medicale U381, 67200 Strasbourg, France
Genes encoding homeodomain-containing proteins potentially involved in endocrine pancreas development
were isolated by combined in silico and nested-PCR approaches. One such transcription factor, Arx, exhibits
Ngn3-dependent expression throughout endocrine pancreas development in , -precursor, and  cells. We
have used gene targeting in mouse embryonic stem cells to generate Arx loss-of-function mice. Arx-deficient
animals are born at the expected Mendelian frequency, but develop early-onset hypoglycemia, dehydration,
and weakness, and die 2 d after birth. Immunohistological analysis of pancreas from Arx mutants reveals an
early-onset loss of mature endocrine  cells with a concomitant increase in - and -cell numbers, whereas
islet morphology remains intact. Our study indicates a requirement of Arx for -cell fate acquisition and a
repressive action on - and -cell destiny, which is exactly the opposite of the action of Pax4 in endocrine
commitment. Using multiplex reverse transcriptase PCR (RT–PCR), we demonstrate an accumulation of Pax4
and Arx transcripts in Arx and Pax4 mutant mice, respectively. We propose that the antagonistic functions of
Arx and Pax4 for proper islet cell specification are related to the pancreatic levels of the respective transcripts.
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The pancreas plays a major role in nutritional homeo-
stasis through synthesis and secretion of hormones and
enzymes. This organ includes endocrine, acinar, and
ductal cell types, all deriving from a common set of epi-
thelial cells that originate in the early gut endoderm.
The exocrine pancreas develops to form acinar cells and
a highly branched ductal epithelium, whereas endocrine
cells aggregate into islets of Langerhans. The latter are
specialized micro-organs composed of four different cell
types, , , , and PP cells, which produce the hormones
glucagon, insulin, somatostatin, and PP (pancreatic poly-
peptide), respectively. Insulin and glucagon function co-
ordinately to control glucose homeostasis, whereas so-
matostatin and PP regulate the secretion of other hor-
mones and of exocrine enzymes (Adrian et al. 1978;
Roncoroni et al. 1983; Csaba and Dournaud 2001). The
first morphological signs of pancreas development ap-
pear at embryonic day 9.5 (E9.5) as dorsal and ventral
protrusions of the primitive gut epithelium that will
later fuse to form the definitive pancreas (for review, see
Edlund 2002). Concomitantly, the glucagon-producing 
cells are the first endocrine cells detected (Herrera et al.
1991; Teitelman et al. 1993; Upchurch et al. 1994). One
day later (E10.5), a few insulin-producing cells appear,
often coexpressing glucagon (Teitelman et al. 1993). At
E14, the secondary transition, as defined by Pictet and
Rutter (Pictet et al. 1972), leads to the generation of nu-
merous fully differentiated  cells. Endocrine cells start
to become organized in small aggregates, and within the
next 24 h, the first somatostatin-producing  cells
emerge (Pictet et al. 1972). Finally, at E18, shortly before
birth, PP-producing cells differentiate, whereas endo-
crine cells begin to form well-organized islets of Langer-
hans.
Until recently, the mechanisms underlying the gen-
eration of these different endocrine cell types was not
well understood, but lineage studies and the generation
of mice deficient for a number of pancreatic transcrip-
tion factors have provided major insights into the control
of islet development. One such transcription factor is
Neurogenin3 (Ngn3), a basic helix–loop–helix (bHLH)
protein-encoding gene member of the neurogenin/neu-
roD family, which is first detected in the pancreatic epi-
thelium at E9 (Sommer et al. 1996; Apelqvist et al. 1999;
Jensen et al. 2000; Schwitzgebel et al. 2000). Ngn3 loss-
of-function mutant mice fail to develop endocrine cells
(Gradwohl et al. 2000), whereas ectopic expression of
Ngn3 under the control of the pdx1 promoter leads to the
differentiation of the entire pancreas into endocrine cells
(Apelqvist et al. 1999; Schwitzgebel et al. 2000). The pro-
endocrine function for Ngn3 suggested by these data was
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further demonstrated by lineage studies using the Cre/
LoxP system (Gu et al. 2002). Hence, whereas Ngn3 ac-
tivation in pancreatic progenitor cells promotes an en-
docrine commitment, the specification of the four differ-
ent islet subtypes appears to be controlled by other
genes. A number of homeodomain-containing transcrip-
tion factors have been characterized for their implication
in each of the pathways leading to differentiated endo-
crine cell subtypes using loss-of-function mutant mice.
Two groups can be distinguished on the basis of their
colocalization with Ngn3; the early factors found in
Ngn3-expressing cells (Nkx2.2, Nkx6.1, Pdx1, and Pax4)
and the late factors (Brn4, Isl1, and Pax6) present in ma-
ture endocrine cells that are devoid of Ngn3 expression
(Jensen et al. 2000; Schwitzgebel et al. 2000).
The paired-box-containing factor Pax4 is selectively
expressed in the developing islets of Langerhans and is
later restricted to mature endocrine cells (Smith et al.
1999; Dohrmann et al. 2000). Pax4-deficient mice de-
velop severe diabetes at birth as a result of altered islet
cell development characterized by a deficiency of  and 
cells, together with an increase of the -cell population
(Sosa-Pineda et al. 1997). Similarly, the NK-homeodo-
main protein-encoding genes, Nkx6.1 and Nkx2.2, are
required for endocrine specification. Mice homozygous
for a targeted deletion of either gene have a reduced num-
ber of  cells. In addition, a decrease in the number of 
and PP cells is found in Nkx2.2 mutant mice. Nkx6.1
expression is abolished in these animals, suggesting that
Nkx2.2 acts upstream Nkx6.1 (Sussel et al. 1998; Sander
et al. 2000).
In contrast, the late factors Brain-4, Isl1, and Pax6 act
on the development and the maintenance of differenti-
ated islet cells. Targeted disruption of the paired-
box-containing gene Pax6 or of the LIM homeo-
domain protein-encoding gene Isl1 leads to a drastic re-
duction of all endocrine subtypes (Ahlgren et al. 1997;
Sander et al. 1997; St-Onge et al. 1997). Brain-4 (Brn-4), a
POU-homeodomain-containing protein, is expressed in
the pancreatic anlage of the mouse foregut at E10 in glu-
cagon-producing cells and seems to transactivate
glucagon gene expression (Hussain et al. 1997). However,
loss-of-function mutant mice do not exhibit any defect
in -cell formation (R.S. Heller and P. Serup, in prep.),
although ectopic expression of Brn-4 targeted to  cells
leads to the coexpression of insulin and glucagon in this
cell type (Hussain et al. 2002). These data suggest a role
of Brn4 in the advanced islet to promote hormone
expression. Similarly, Pdx1, a homeodomain-contain-
ing protein involved in pancreatic bud formation
(Jonsson et al. 1994; Guz et al. 1995; Offield et al. 1996),
plays an additional role in maintaining the -cell pheno-
type. Using the Cre/Lox system, Ahlgren at al. (1998)
demonstrated that -cell-targeted deletion of Pdx1 leads
to the loss of this cell type. Taken together, these data
suggest that islet progenitors are progressively com-
mitted to an islet fate, specified to a particular endocrine
cell subtype and finally maintained in this commit-
ment.
In this study, we describe the functional characteriza-
tion of Arx in the endocrine pancreas. The homeobox-
containing gene, Arx, which is localized on the X chro-
mosome (Blair et al. 2002), was first reported to be ex-
pressed in the mouse central nervous system (CNS) by
Miura et al. (1997). Recently, Arx dysfunction has been
associated with diverse forms of X-linked mental retar-
dation and epilepsy in humans (discussed in Hirose and
Mitsudome 2003). Interestingly, by means of in situ hy-
bridization, we observed a previously unnoticed expres-
sion in the pancreas, at the onset of pancreatic bud evagi-
nation, which later becomes restricted to the islets of
Langerhans. To investigate the role of this gene in pan-
creas development, we generated loss-of-function mu-
tant mice. Arx-deficient animals die 2 d after birth, after
having developed severe hypoglycemia. Immunohisto-
chemical analysis of Arx mutant pancreas revealed an
absence of  cells and an increased number of  and 
cells. However, the total number of endocrine cells is
unaffected, suggesting a role for Arx in promoting -cell
fate. This is opposite to the phenotype observed in Pax4-
deficient mice, and we demonstrate that a mutual inhi-
bition of Arx and Pax4 during early stages of endocrine
development is required to generate normal islets of
Langerhans.
Results
Arx is expressed in endocrine pancreas progenitors
Aiming to identify members of the homeobox-contain-
ing gene family with a potential role in islet of Langer-
hans genesis, we undertook a search combining in silico
and nested-PCR, using a mouse cDNA pancreas library
as a template (P. Collombat, A. Mansouri, and P. Gruss,
in prep.). Several genes with previously unnoticed ex-
pression in this organ were isolated, including Arx, a
gene encoding a homeodomain-containing protein. Arx
expression was described previously in the mouse cen-
tral nervous system, starting from E9.5 (Miura et al.
1997). Importantly, at this particular stage, we detected
expression of Arx in the pancreas anlage (Fig. 1A, arrow-
head in B). Arx-expressing cells were found during the
genesis of this organ, in the proliferating epithelium (Fig.
1C), the differentiating pancreatic precursors (Fig. 1D),
and subsequently, in the forming islets of Langerhans
(Fig. 1E).
To determine whether Arx played a role in endocrine
cell development,Arx expression was studied in the pan-
creas of mice mutant for the pro-endocrine Ngn3 gene.
At E14.5, just before the peak of endocrine cell produc-
tion, examination of the pancreas of Ngn3 mutant em-
bryos revealed a complete loss of Arx expression (Fig.
1G,I). This result was further confirmed by RT–PCR per-
formed in wild-type and Ngn3 mutant pancreas (Fig. 1,
RT–PCR panel). Taken together, our data indicate new
expression domains of Arx in the developing pancreas.
Notably, the lack of Arx transcripts in the pancreas of
Ngn3-deficient mice suggests a potential role of Arx
downstream of Ngn3 in islet of Langerhans developmen-
tal processes.
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Generation of Arx loss-of-function mutant mice
To gain insight into the potential function of Arx during
pancreas development, we generated loss-of-function
mutant mice by homologous recombination in embry-
onic stem (ES) cells. A targeting vector was designed to
delete the two first exons corresponding to the N-termi-
nal 360 amino acids (Fig. 2A). These two exons, which
encode the octapeptide (Eh1 domain), -helix 1 and ap-
proximately half -helix 2 of the homeodomain, were
replaced by the -galactosidase gene and the Neomycin
resistance gene flanked by LoxP sites. Of the 202 stably
transfected ES clones obtained after antibiotic selection,
two were homologous recombinants as identified by
Southern analysis (Fig. 2B). Because the Arx gene is lo-
calized on the X chromosome (Blair et al. 2002), and ES
cells were derived from male blastocysts, we therefore
detected either the wild-type (designated as X+) or the
mutated (designated as X−) allele. Chimeras obtained
from the targeted ES cell clones were bred to NMRI mice
with successful germ-line transmission. Heterozygous
X+/X− females of the mixed background (129Sv × NMRI)
were crossed with wild-type males (X+/Y), and both sex
and genotype of the offspring were determined by PCR
(Fig. 2C). In situ hybridization demonstrated that our
targeting approach deleted theArx gene, as its expression
was undetectable using a full-length cDNA-derived
probe (Fig. 2D, bottom). The following allelic frequencies
were obtained: 52.3% wild-type (X+/X+ females and X+/Y
males), 24.2% heterozygous (X+/X− females), and 23.5%
null (X−/Y males; n = 189); such a Mendelian ratio indi-
cates that the deletion of the Arx gene did not result in
embryonic lethality. No obvious difference was observed
between heterozygous and wild-type animals. We there-
fore used mice of both genotypes as controls throughout
this study.
Arx-deficient mice exhibit severe hypoglycemia prior
to death
Arx loss-of-function mutant mice have been described
previously (Kitamura et al. 2002). They are born at E19.5
and die within 12 h. Compared with wild-type animals,
they have a small brain, reduced olfactory bulbs, and
altered testes. However, the precise cause of death was
not ascertained.
The Arx-deficient mice generated in the present study
(X−/Y males) are indistinguishable from wild-type or het-
erozygous littermates at birth. Phenotypic discrepancies
appear within the first day postpartum; despite normal
feeding, as evidenced by the presence of milk in the
stomach, Arx mutants display retarded growth, are de-
hydrated, and die at postnatal day 2 (P2; Fig. 2D, top).
Figure 1. Arx is expressed in normal mouse pancreas,
but not in that of Ngn3-deficient animals. (A,B) Whole-
mount in situ hybridization of an E9.5 mouse embryo.
Sagittal section (A) and enlarged view of the pancreatic
area (B), revealingArx transcripts in the pancreas anlage
(arrowhead in B). (C–E) When analyzed by in situ hy-
bridization, pancreas sections display widespread Arx
expression at E12.5 (C), E14.5 (D), and E16.5 (E). (F–I)
Detection of glucagon and Arx expression by in situ
hybridization in E14.5 wild-type (F,G) and Ngn3 homo-
zygous mutant animals (H,I). Ngn3 mutant pancreas
lacks Arx expression. (RT–PCR) RT–PCR analysis per-
formed on mRNA from E14.5 wild-type or Ngn3 mu-
tant animals (left and middle lanes, respectively). RT–
PCR controls were performed with primers designed
from the glucose-6-phosphate dehydrogenase (G6PDH)
and the TATA-box-binding protein (TBP) reference
genes; positive controls with primers from the amylase
gene and negative controls were assayed with water in-
stead of DNA template (right lane). RT–PCR results
confirm a lack of glucagon and Arx expression in Ngn3
mutant mice.
Arx and Pax4 control endocrine cell fate
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Figure 2. Disruption of the Arx gene by homologous recombination and genotype analysis of heterozygous intercrosses. (A) Maps of
the wild-type Arx locus, targeting vector, and disrupted Arx allele. Exons are indicated as black rectangles with encoded protein motifs
underneath. The 1.3-kb 5 external probe used for Southern blotting is shown at left. (B) BamHI, (H) HindIII, (I) EcoRI, (II) HincII, (V)
EcoRV, (X) XhoI, (TK) Herpes simplex virus thymidine kinase gene. (B) Southern analysis of EcoRI-digested DNA from three male ES
clones, Arx being located on the X chromosome, either the 10.5-kb wild-type allele (+) or the 5.7-kb mutated allele (−) is detected. (C)
Genotyping and sex characterization by PCR of a litter from an intercross of heterozygous mice. (Top gel) Sex determination using Sry
gene-derived primers producing a 350-bp band in the case of male genomic DNA. (Bottom gel) Three genotyping primers (represented
by green and red arrows inA) were used to generate the wild-type (258-bp) andmutant (470-bp) allele bands. (D) Photograph of 2-day-old
wild-type (left) andArxmutants (right) with the corresponding transverse sections of neural tubes assayed by in situ hybridization with
an Arx-cDNA-derived-probe (bottom). Arx-deficient animals are smaller and dehydrated and die at this stage. The loss of Arx expres-
sion in mutant mice demonstrates that Arx is inactivated. (E) Blood glucose analysis in the offspring of F1 hybrids 12 h (P12h), 24 h
(P24h), and 48 h (P48h) after birth indicates that Arx-disrupted animals exhibit severe hypoglycemia that plunges shortly before death
(p48h-SBD). Values are means ± S.E. of the mean (S.E.M.) and are representative of at least 20 animals. Differences between glucose
levels were statistically significant by Student’s t-test (***) at P48h between wild-type/heterozygous and mutant animals (p < 0.001).
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The different phenotypic alterations exhibited by the
Arx mutant mice generated by Kitamura et al. (2002),
such as early birth and shortened life-span, most prob-
ably originate in the different targeting strategies; thus,
Kitamura et al. (2002) inserted a STOP–IRES–LacZ–Neo-
mycin resistance cassette downstream of the second
exon of the Arx gene. Consequently, it cannot be ex-
cluded that a gain-of-function mutation was generated.
In contrast, our knockout construct was generated by
specifically deleting the two first exons. We further dem-
onstrate the absence of full-length Arx transcripts by in
situ hybridization and RT–PCR analysis (Fig. 2D, bot-
tom; data not shown).
To determine whether the observed lethality was
related to anomalous endocrine pancreatic function,
blood glucose levels were measured. Twelve hours after
birth, glycemia appeared normal in all littermates
(Fig. 2E). The first differences were observed 1 d post-
partum; whereas wild-type and heterozygous animals
displayed a normal blood glucose level, that of the
mutants was slightly decreased. However, 2 d after birth,
the mice lacking a functional Arx gene exhibited a se-
vere hypoglycemia (46.72 ± 14 mg/dl, n = 36), which
dropped sharply shortly before death (<10 mg/dl, n = 26),
in contrast to age-matched wild-type (85.67 ± 12 mg/dl,
n = 26) and heterozygous (80.72 ± 11 mg/dl, n = 32)
animals.
Arx mutant mice display a loss of mature  cells
concomitant with an increase in - and -cell numbers
To decipher the role of Arx in endocrine pancreatic dif-
ferentiation, histological analysis of pancreas from
2-day-old control and Arx mutant mice was performed.
The general morphology of the pancreas and the islets of
Langerhans appeared normal (Fig. 3A,B). Similarly, a ki-
netic analysis in islets, using X-Gal staining, recapitu-
lated the previously observed Arx expression pattern,
both in heterozygous and mutant animals (Miura et al.
1997; data not shown). More specifically, X-Gal-stained
cells were detected in the pancreatic epithelium as early
as E10.5 (Fig. 3C–F). An expansion of pancreatic -galac-
tosidase-labeled cells was seen between this stage and
E16.5, together with endocrine cell development (Fig.
3G,J). The first discrepancies between heterozygous and
mutantArxmice arise at this stage and persist after birth
with an increase in the number of X-Gal-positive cells in
mutant animals (Fig. 3I–L).
Islets were further subjected to a molecular phenotype
analysis using immunohistochemistry to detect the
presence of endocrine cell-subtypes producing insulin,
glucagon, somatostatin, or PP. Strikingly, P2 Arx-defi-
cient animals were completely lacking glucagon-produc-
ing  cells in the islets of Langerhans (Fig. 4D,M). We
were not able to detect any glucagon-producing cells,
even using higher antibody concentrations or different
glucagon antibodies (data not shown). Concomitantly,
there was a dramatic increase in the somatostatin-pro-
ducing cell population of Arx mutant animals (Fig.
4E,N). Colocalization experiments with  cells allowed
us to clearly demonstrate that  cells also exhibited an
abnormal distribution within the islet of Langerhans. In
normal pancreas, at approximately E18, endocrine cell
aggregates begin to develop the architecture of mature
islets (Slack 1995), characterized by a core of  cells sur-
rounded by a mantle of , , and PP cells (Fig. 4G–I). In
Arx mutants,  cells were no longer localized to the
Figure 3. Arx expression assessed by LacZ staining demon-
strates an increase in the number of -galactosidase-producing
cells within the islet of Langerhans in Arx-deficient mice. (A,B)
Hematoxylin-eosin staining of 2-day-old pancreas sections re-
veals no morphological discrepancy between heterozygous (A)
and mutant (B) Arx mice. (C,D) Whole-mount LacZ staining of
Arx-deficient embryos (C) and enlarged view (D) reveals -ga-
lactosidase expression in the pancreas as early as E10.5, as well
as in additional hitherto unmentioned domains. Pancreas sec-
tions of heterozygous (E,G,I,K) andmutant (F,H,J,L)Arx animals
were examined for -galactosidase activity by X-Gal staining at
different developmental stages as follows: E10,5 (E,F, outlined),
E12.5 (G,H), E16.5 (I,J), and P2 (K,L). -galactosidase-positive
cells present a similar distribution at early embryonic stages in
wild-type and mutant pancreas. After E16.5, the content of -ga-
lactosidase-producing cells is increased in mutant animals as
compared with littermates. Each picture is representative of at
least eight animals from different litters.
Arx and Pax4 control endocrine cell fate
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mantle zone, but could be seen scattered in the core of
the islet (Fig. 4E,H,N,Q). In addition, we observed a
slight increase of insulin-producing -cell number
within the islets of Langerhans (Fig. 4A–C,J–L), whereas
the number of PP-producing cells appeared normal (Fig.
4F,O). To confirm and quantify these differences, we se-
rially sectioned whole P2-pancreas and determined the
number of insulin-, glucagon-, somatostatin-, and PP-
positive cells in every tenth section. The data from this
analysis confirm the complete loss of glucagon-produc-
ing cells in mutant mice, whereas the mean number of
somatostatin- and insulin-expressing cells per section
was increased, 2-fold and 1.3-fold, respectively, in Arx
mutants as compared with their heterozygous or wild-
type littermates (Table 1). The average PP-cell number
per section was not modified significantly. Collectively,
our data indicate that Arx deficiency does not alter the
general morphology of the pancreas and suggest that Arx
function is specifically required for the proper apportion-
ment of -, -, and -cell numbers, as well as appropriate
location of the latter.
Arx is differentially required for -, -,
and -cell specification
To determine when the phenotypic alterations observed
in Arx-deficient islets occur, we examined the pancreas
of control and mutant embryos at earlier stages of devel-
opment for the presence of endocrine hormones and
-galactosidase. At E10.5, the number of glucagon-ex-
pressing cells appeared normal (data not shown). Insulin-
expressing cells were observed in mutant pancreas at
this stage, but we were unable to determine whether
their number was altered because very few cells are pres-
ent at this stage, even in wild-type mice. However, at
E12.5, when both insulin- and glucagon-expressing cells
are readily detectable in the normal pancreas, glucagon-
producing cells, often coexpressing the insulin hormone,
were detected in Arx mutant pancreas in normal propor-
tions (Fig. 5A,B). Importantly, none of these hormone-
secreting cells coexpressed the -galactosidase enzyme
in the islets of Langerhans of both genotypes (Fig. 5C,D;
data not shown). These results provide evidence that Arx
Figure 4. Increased - and -cell populations at the expense of  cells in Arx-deficient mice. Single sections of 2-day-old mice were
examined for the presence of pancreatic hormone in control (A–I) and Arxmutant (J–R) animals by coimmunofluorescence. (A–C,J–L)
Insulin-expressing cells were localized in well-defined islets using 488-ALEXA secondary antibody. Codetection experiments were
performed with 594-ALEXA secondary antibody to visualize either glucagon-producing cells (D,M), somatostatin-producing cells (E,N),
or PP-producing cells (F,O), and sections were counter-stained with DAPI (G–I,P–R, in blue). (G–I,P–R) A picture combining codetec-
tion of  cells with other endocrine cells and counter-staining is provided in each case. Note the slight increase of the insulin-
producing cell population (cf. A–C and J–L), the loss of glucagon-secreting cells (cf. D and M), and the increase in the number of
somatostatin-expressing cells (cf. E and N) in Arxmutant animals. Arx deletion also leads to a modification of the spatial distribution
of  cells with an additional localization within the islet core (cf. E,H and N,Q). Each picture is representative of 8–20 animals from
different litters.
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is not implicated in the generation of early insulin/glu-
cagon-producing cells.
In contrast, when assayed at E15.5, islets of Langer-
hans in Arx-deficient mice were found to be completely
lacking glucagon-expressing cells (Fig. 5E,F). At the same
time, an increase of the insulin-producing cell popula-
tion was clearly apparent (Fig. 5G–J). -galactosidase
labeling was detected in all  cells in heterozygous pan-
creas using protein and mRNA detection (Fig. 5E;
data not shown). However, in both genotypes,  cells did
not possess detectable -galactosidase mRNA (Fig.
5G,H). Interestingly, when sections of pancreas of con-
trol and mutant mice were stained with antibodies di-
Figure 5. Alteration of mature endocrine cell-subtype specifi-
cation following Arx inactivation. (A–D) Staining of E12.5 het-
erozygous (A,C) and mutant (B,D) Arx pancreata for insulin
(A,B), glucagon (A–D), and -galactosidase (C,D) proteins,
counter-stained with DAPI (blue). -galactosidase is not ex-
pressed in the early hormone-producing cells. There is no
change in the number of insulin-expressing cells (often produc-
ing glucagon) following Arx deletion. (E–L) Sections of pancreas
from E15.5 (E–J) and E18.5 (K,L) stained with anti--galactosi-
dase (E,F,I–L), anti-glucagon (E,F), anti-Nkx6.1 (G,H), anti-DIG
(G,H, shown in red), anti-insulin (I,J), or anti-somatostatin (K,L)
antisera and counter-stained with DAPI (blue) in heterozygous
(E,G,I,K) or mutant (F,H,J,L) animals except in G and H. (E,F)
Glucagon-secreting cells coexpress -galactosidase and are lack-
ing in mutant pancreas. (G,H)  cells (stained with Nkx6.1 for
technical reasons) do not express -galactosidase in E15.5 mu-
tant and control pancreas. (I,J) The -cell population is increased
in mutant islets. A residual presence of -galactosidase protein
is observed. (K,L) -galactosidase staining is detected in  cells,
which are overrepresented in E18.5 Arx-deficient mice. (M–R)
Endocrine differentiation appears normal following Arx inacti-
vation. Sections of heterozygous (M,O,Q) and mutant (N,P,R)
pancreas were stained with anti-Pax6 (M,N), anti-Ngn3 (O,P), or
anti-Isl1 (Q,R) antisera together with anti--galactosidase anti-
sera and counter-stained with DAPI (blue). (M,N) All -galacto-
sidase-labeled cells coexpress Pax6. Pax6-marked cells are nor-
mally represented in both genotypes. (O,P) Arrows show a few
Arx- and Ngn3-labeled cells. Arx deletion does not alter the
numbers of Ngn3-stained cells. (Q,R) Isl1-marked cells are ex-
clusively found among the -galactosidase-labeled population,
but numerous cells are -galactosidase+/Isl1−, suggesting a func-
tion of Arx in nonmature cells. Similar numbers of Isl1+ cells
are observed in control and Arx mutant pancreas. Each picture
is representative of at least three animals from different litters.
Table 1. Quantification or pancreatic endocrine cell content alterations in Arx-deficient mice
Hormone-producing
cells







Insulin 307 ± 35 (61%) 404 ± 23 (74%) +31
Glucagon 143 ± 26 (28%) 0 —
Somatostatin 44 ± 14 (9%) 135 ± 28 (25%) +207
Pancreatic polypeptide 9 ± 4 (2%) 8 ± 3 (1%) ∼0
Total cells 503 ± 79 547 ± 54 ∼0
Endocrine cells were counted from immunostained sections of 2-day-old pancreas estimated to be the same size. Data are shown as
the mean number ± S.E. of the mean (S.E.M.) of hormone-positive cells per section (every tenth section) from at least three independent
pancreata. Percentages in brackets indicate the contribution of a particular endocrine cell-subtype to the total islet cell population.
Hemizygous Arx pancreas lacks  cells, whereas - and -cell content are increased 1.31- and 2.07-fold, respectively. Importantly, the
total endocrine cell number is unchanged following Arx distribution.
Arx and Pax4 control endocrine cell fate
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rected against -galactosidase and insulin proteins, we
observed residual -galactosidase proteins in insulin-pro-
ducing cells of Arx-deficient embryos (Fig. 5I,J). Because
the stability of the -galactosidase protein allows
the latter to be used as a short-term lineage tracer, our
results suggest that -galactosidase-expressing  cells
observed in mutant animals derive from Arx-depleted
cells.  cells were also positive for -galactosidase pro-
tein and mRNA (Fig. 5K,L; data not shown). As early as
E18.5, Arx-depleted animals had developed more somato-
statin/-galactosidase-labeled cells than control mice, sug-
gesting that Arx-deficient cells also adopt a -cell fate.
To further elucidate the molecular nature of the de-
fects observed following Arx deletion, an extensive im-
munohistochemical analysis of the transcription factors
involved in endocrine determination was performed.
Sections of E14.5 pancreas were first incubated with an-
tisera against -galactosidase together with antisera
against the Pax6, Ngn3, or Isl1 proteins (Ahlgren et al.
1997; Sander et al. 1997; Gradwohl et al. 2000). In control
and Arx mutant animals, -galactosidase staining was
detected in Pax6-postive cells (Fig. 5M,N), Ngn3-labeled
cells (Fig. 5O,P, arrowheads), and the vast majority of Isl1-
stained cells (Fig. 5Q,R). Interestingly, the total numbers of
Pax6-, Ngn3-, and Isl1-marked cells were not modified fol-
lowing Arx deletion. Similarly, examination of the expres-
sion of various additional transcription factors shown pre-
viously to play a role in endocrine cell specification, such
as Nkx2.2, Nkx6.1, Pdx1, and HB9 (Harrison et al. 1994;
Sussel et al. 1998; Li et al. 1999; Sander et al. 2000), dem-
onstrated that they were all present and appropriately lo-
calized in heterozygous and mutant Arx animals.
Taken together, our results demonstrate the presence
of two distinct populations of insulin- and glucagon-la-
beled cells during pancreas development. Arx does not
act on the generation of the early hormone-producing
cells. Instead, it is required for the specification of ma-
ture endocrine cells, as evidenced by the increased popu-
lation of  and  cells and the loss of  cells in Arx-
deficient mice. In addition, similar numbers of Ngn3-
stained endocrine precursors and Isl1-labeled post-
mitotic endocrine cells were detected in control and
mutant mice. Importantly, no alteration in the total islet
cell number was detectable after birth. We therefore con-
clude that the lack of a functional Arx allele causes
-cell progenitors to adopt an alternative - or -cell fate.
Arx and Pax4 are up-regulated in Pax4 and Arx
mutant mice, respectively
Strikingly, the deduced instructive function of Arx in
specifying -cell-subtype fate at the expense of - and
-cell destiny is the reverse of that attributed to the
paired-box-containing factor Pax4. Mice homozygous for
a mutant allele of Pax4 also exhibit an altered pancreatic
endocrine cell-subtype ratio, characterized by an in-
creased -cell population and drastically reduced - and
-cell numbers (Sosa-Pineda et al. 1997). Such opposing
phenotypic alterations are strongly suggestive of antago-
nistic functions of Pax4 and Arx during endocrine speci-
fication. To shed light on potential cross-regulatory
functions of Pax4 and Arx in this phenomenon, we as-
sayed pancreatic Pax4 and Arx mRNA content by mul-
tiplex RT–PCR in Arx and Pax4-deficient mice, respec-
tively. The pancreas of Pax4 mutant animals contained
3.3 times moreArxmRNA than the control at E14.5 (Fig.
6A), whereas the content of Pax4 transcripts was four-
fold higher in the pancreas ofArx-depleted mice (Fig. 6B).
Hence, our data clearly demonstrate that Arx inactiva-
tion results in an accumulation of Pax4 transcripts as-
sociated with an increased number of  and  cells. Con-
versely, Pax4 inactivation is accompanied by a rise in
Arx mRNA levels, leading to an over-representation of
the  cells in mature islets. We conclude that Arx and
Pax4 have opposing actions on the specification of endo-
crine subtype destiny through an inhibitory cross-regu-
latory circuit that controls the transcriptional state of
these two genes.
To determine whether this interaction reflects mecha-
nisms involving individual or different cells, we ana-
lyzed Arx and Pax4 at the single-cell level. Due to the
lack both of a suitable Pax4 antisense probe and of an
antibody directed against Pax4, we assayed Pax4 expres-
sion using the -galactosidase reporter gene present in
heterozygous Pax4 pancreas. The recent generation of an
anti-Arx antibody (recapitulating the Arx expression pat-
tern, as demonstrated in Fig. 6C,D) allowed us to code-
tect Arx and Pax4 proteins in single islet cells as early as
E13.5 (Fig. 6E). As the proliferation of glucagon and in-
sulin-expressing cells proceeds, Arx and Pax4 were found
to be coexpressed, but in 27% less cells (arrows in Fig.
6F), whereas the number of cells expressing either Arx or
-galactosidase increases. These data suggest that Arx
and Pax4 are first found together in endocrine progeni-
tors, however, as development continues, one of the fac-
tors prevails and the predominant protein will determine
the fate of the endocrine cell. To find out whether this is
achieved through direct interaction between Pax4 and
Arx, we also examined Arx expression in Pax4-deficient
embryos at E14.5 (Fig. 6G). We observed a 64% increase
in the number of cells doubly positive for -galactosidase
and Arx proteins (Fig. 6, cf. F and G), thereby further
demonstrating that Arx expression is up-regulated in the
absence of functional Pax4.
Discussion
In this study, the consequences of the loss-of-function of
the Arx gene on the differentiation of the endocrine pan-
creas are presented. In fact, although Arx has been inac-
tivated previously in the mouse, resulting in abnormal
differentiation and proliferation of the brain and testes,
no expression or defect in the pancreas has been de-
scribed (Kitamura et al. 2002). Our analysis clearly es-
tablishes that Arx transcripts are detectable as early as
E9.5 in the pancreatic epithelium and are later found in
mature  and  cells. Mice carrying a targeted disruption
of the Arx gene develop severe hypoglycemia, weakness,
dehydration, and die 2 d after birth. Detailed examina-
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tion of the pancreas reveals an early-onset loss of the
mature -cell population, concomitant with an augmen-
tation of - and -cell types, as well as an abnormal dis-
tribution within islets for the latter subtype.
Role of Arx in endocrine specification
By irreversibly tagging the progeny of cells via the Cre/
LoxP system, Herrera (2000) clearly demonstrated that
adult glucagon- and insulin-producing cells do not derive
from cells that coexpressed both hormones previously,
but rather emerge through distinct pathways. This study
suggests that, throughout the development of the islet of
Langerhans, two different populations of insulin-produc-
ing cells are generated successively, as well as two dis-
tinct types of glucagon-expressing cells. Other data have
confirmed the existence of two insulin-expressing cell
populations (Oster et al. 1998; Sander et al. 2000), and
our results corroborate this finding. Importantly, we also
clearly demonstrate the presence of two distinct gluca-
gon-expressing cell types. In Arxmutant islets of Langer-
hans, the development of the early glucagon-/insulin-
expressing cells remains unaffected, but mature  cells
fail to appear at later stages, whereas the number of ma-
ture  and  cells is increased. Interestingly, Arx labeling
was observed at an early developmental stage, but never
in hormone-expressing cells. In contrast, Arx expression
was detected after E14.5, in , -precursors, and later in
 cells, further demonstrating that mature endocrine
cells emerge from endocrine progenitors that did not ex-
press hormone previously.
Our finding that in Arx-deficient embryos -, -, and
-cell content is significantly modified without alter-
ation in shape, size, or total endocrine cell number sug-
gests a replacement of the mature  cells by  and  cells.
Accordingly, Arx seems to determine the relative fate of
these cells. This hypothesis is reinforced by the loss of
Arx expression in the pancreas of Ngn3-deficient mice
and the fact that pancreas from Arx mutant mice con-
tains normal proportions of early Ngn3-labeled endo-
crine progenitors and Isl1-marked post-mitotic endo-
crine cells, as well as Nkx2.2-, Nkx6.1-, Pdx1-, and HB9-
positive cells. Taken together, our data demonstrate that
in Arx-deficient animals, -, -, and PP-cell developmen-
Figure 6. Increase of Arx and Pax4 tran-
script levels in the pancreas of Pax4- and
Arx-deficient mice, respectively. Multi-
plex amplification of pancreatic mRNA
from Pax-4 (A) and Arx (B) mutant mice at
E14.5. The genotypes of control and mu-
tant mice are indicated above the gel
scans. Measurements of the intensity of
radioactive Arx and Pax4 PCR products,
after normalization with the coamplified
TATA-box-binding protein (TBP) ampli-
con, are represented as graphs. Below are
indicated the average normalized intensi-
ties in control and mutant mice as well as
their relative difference; the Arx transcript
content is 3.3-fold higher in E14.5 Pax4
mutant pancreas compared with control
animals. Arx-deficient pancreas contains
four times more Pax4 mRNA at the same
embryonic stage. (C,D) An anti-Arx anti-
body recapitulates Arx expression pattern
at E11.5 (sagittal section in C and enlarged
picture in D) in the forebrain (FB) and the
floor plate of the diencephalon (Fp). (E–G)
Analysis of Arx (red) and -galactosidase
(green) expression in Pax4 heterozygous
(E,F) and homozygous (G) pancreas. The
average percentage of Arx+/-galactosi-
dase+ cells from three serially sectioned
pancreata is indicated below each picture.
(E) In Pax4 heterozygous pancreas, Arx is
found colocalized with the -galactosidase
protein at E13.5 in 35% of endocrine cells.
(F) At E14.5, only 8% of islet cells are
Arx+/-galactosidase+. (G) At the same
stage, in Pax4 homozygous pancreas, this
number increases with a codetection of
Arx and -galactosidase found in 72% of
the endocrine cells.
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tal processes are normal and lead to the generation of
well-formed islets of Langerhans. However,  cells fail to
appear, whereas - and -cell numbers are increased. We
conclude that Arx promotes the acquisition of -cell fate
by endocrine progenitors and does so by antagonizing -
and -cell commitment.
Arx and Pax4 act as differential regulators
of endocrine cell fate
The results presented above indicate that Arx plays a key
role in differential specification of islet cells. However,
little is known of the processes underlying such a func-
tion; only the Pax4 gene has been shown to act differen-
tially on endocrine cell destiny (Sosa-Pineda et al. 1997),
as Pax4 deletion leads endocrine progenitors to adopt an
alternative cell-subtype fate. The modifications of the
islet-cell subtype content observed in these mutant mice
are reminiscent of those seen inArx loss-of-functionmu-
tant animals. Pax4- and Arx-depleted pancreas displays
inversed alterations in -, -, and -cell ratio. The abnor-
malities seen in Arx- and Pax4-deficient mice suggest
antagonistic roles for these two transcription factors. Us-
ing multiplex RT–PCR, we established that Pax4mRNA
is up-regulated in Arx mutant mice, and that the Arx
transcript content is increased in Pax4-deficient pan-
creas. Furthermore, the recent generation of an anti-Arx
antibody allowed us to demonstrate that Arx and Pax4
(the latter assayed by -galactosidase staining in hetero-
zygous Pax4 animals) are colocalized in early endocrine
pancreas, but not at later developmental stages. Interest-
ingly, our data suggest that in endocrine progenitors, one
of these factors will ultimately predominate; if it is Pax4,
- and -cell fates will be specified, whereas Arx will
favor -cell commitment. Hence, we conclude that
proper islet of Langerhans formation requires a tight con-
trol of the relative levels of Arx and Pax4 mRNA, prob-
ably achieved via mutual inhibition.
Our data, together with the results obtained by others
(Sander et al. 1997; Sosa-Pineda et al. 1997; Mansouri et
al. 1999; Gradwohl et al. 2000), allow us to propose the
model depicted in Figure 7. In endocrine progenitors, Arx
promotes -cell fate and antagonizes - and -cell des-
tiny, whereas Pax4 favors - and -cell fates at the ex-
pense of -cell destiny. Our results suggest that these
opposing activities are the consequences of a mutual
cross-regulatory inhibition of these factors. The detailed
mechanisms involved remain to be elucidated. Simi-
larly, further work will be required to determine poten-
tial downstream target genes of Pax4 and Arx involved in
endocrine subtype determination. In this respect, a re-
cent study by Huotari et al. (2002) has implicated EGF
signaling. Using pancreatic explant cultures, the authors
have demonstrated that the EGF receptor family-binding
proteins Betacellulin and Neuregulin-4 promote - and
-cell fates, respectively, in each case, at the expense of
-cell destiny. These results are consonant with the phe-
notype of Arx loss-of-function mice. To decipher the
mechanisms involved in endocrine subtype commit-
ment, a thorough examination of (1) Arx and Pax4 ex-
pression in mice with perturbed ErbB signaling and (2)
EGF signaling in Arx and Pax4mutant mice would be of
particular interest. Similarly, the double inactivation of
Arx and Pax4 and ectopic expression of either gene
would permit us to unravel the interaction between
these two factors.
In summary, our analysis establishes a requirement of
Arx for proper endocrine cell specification. We provide
strong evidence that Arx and Pax4 play opposite roles in
this process. Because the islet hormones, especially in-
sulin and glucagon, have a central function in nutriment
metabolism, alterations in the expression of Arx in the
islets of Langerhans could modify nutriment homeosta-
sis in the whole organism. Mutations of the human ARX
gene have been associated with a particular type of X-
linked lissencephaly with abnormal genitalia (Kitamura
et al. 2002); it would be interesting to determine whether
mutations in the human ARX gene are, additionally or
independently, associated with glucose homeostasis de-
regulation.
Material and methods
Targeted disruption of the Arx gene
To generate Arx mutant mice, two overlapping clones contain-
ing the entire Arx gene were isolated from a 129/Sv mouse
Figure 7. Schematic model representing the transcription fac-
tors implicated in the specification of the endocrine pancreas,
on the basis of temporal expression and phenotypic results of
specific gene deletions. Circles represent endocrine cells at par-
ticular developmental stages. The different transcription factors
expressed in a particular cell type are indicated within the
circles. Arrows represent different (hypothetical) endocrine dif-
ferentiation steps. Loss-of-function mutant mice phenotypes
demonstrate antagonistic endocrine-specifying activities for
Arx and Pax4; Pax4 promotes - and -cell fates, whereas Arx
favors -cell destiny. The question mark indicates a fate re-
maining to be elucidated. For the purpose of simplification, exo-
crine/ductal- and PP-cell development are not represented.
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genomic library (provided by Anton Berns, Amsterdam). The
gene was mapped using a combination of Southern analysis and
restriction enzyme digests. The targeting construct is depicted
in Figure 2A. Briefly, aiming to delete the ATG start-codon
without altering any potential regulatory element, a 2.0-kb di-
gested HindIII/EcoRV 5 fragment was ligated to a 450-bp PCR-
amplified fragment designed to encompass the region just up-
stream of the ATG start-codon. The 2.5-kb fragment obtained
was ligated to a cassette containing a fusion of a nuclear local-
ization signal (NLS) in-frame with the -galactosidase gene
[kindly provided by M. Buckingham (Pasteur Institute, Paris,
France)]. Downstream, we inserted the Neomycin resistance
gene flanked by LoxP sites. Next, the fragment encompassing
the former 2.5-kb 5 fragment, the NLS--galactosidase gene
and the LoxP-Neomycin resistance gene was ligated upstream
of an 8.1-kb XhoI/BamHI 3 fragment. Finally, the Herpes sim-
plex virus-thymidine kinase cassette was added in the 3 posi-
tion. The XhoI enzyme was used to linearize our construct prior
to electroporation into ES cells.
Generation of mutant animals
The generation of recombinant ES clones and Arxmutant mice
was performed as described by Mansouri (2001). A total of 202
stably transfected ES clones were obtained after antibiotic se-
lection. Clones were screened for the presence of the disrupted
Arx gene by Southern blotting with a 1.3-kb HincII-digested 5
external probe (shown in Fig. 3A). Mutant ES cells were aggre-
gated with NMRI 8-cell-stage embryos using standard tech-
niques. Chimeric male mice were obtained and mated to NMRI
females to generate heterozygous animals. Mice were geno-
typed by PCR using a mixture of three primers (Fig. 2A) to
identify the wild-type and the mutant alleles, generating a 0.25-
kb and a 0.4-kb PCR product, respectively (P1, CGGCTCAC
TACACTTGTTACCGCTTGTCC; P2, AGCAGCCCTCTTCC
TGGTACTGATTGCTC; and P3, TGCTGCAAGGCGATAAG
TTGGGTAACGC).
-galactosidase staining
Whole embryos or tissues were isolated and the yolk sac saved
for DNA preparation and genotyping. After fixation in 4% para-
formaldehyde, embryos and tissues were washed in PBS and
then incubated in staining solution [4 mM K3 [Fe(CN)]6], 4 mM
K4[Fe(CN)6], 0.02% NP-40, 0.01% Na-deoxycholate, 5 mM
EGTA, 2 mM MgCl2, and 0.4 mg/mL 5-bromo-4-chloro-3-
inodolyl-D-galactopyranoside. Prior to sectioning, tissues were
dehydrated through ethanol series, cleared in toluene, and em-
bedded in paraffin.
Hematoxylin-eosin staining
Paraformaldehyde-fixed tissues, embedded in paraffin, were cut
in 6-µm sections and applied to Probe-on Plus slides (Fisher
Scientific). Tissues were incubated after rehydration in hema-
toxylin for 2.5 min, rinsed in water, dipped quickly in 0.5%
HCl/70% ethanol (v/v), and washed in water. After immersion
in 0.2% NaHCO3, they were rinsed in water, dipped in 0.1%
eosin for 20 sec, and washed briefly in water before dehydration
and mounting.
RNA in situ hybridization
For whole-mount RNA in situ hybridization, tissues were iso-
lated, fixed in 4% paraformaldehyde, and dehydrated through
methanol series. Rehydrated embryos were bleached in 6%
H2O2 for 1 h, permeabilized with 10 µg/mL proteinase K for
1–15 min, and prehybridized at 70°C for 90 min in a medium
containing 50% formamide, 5× SSC at pH 4.5, 50 µg/mL yeast
tRNA, 50 µg/mL heparin. Hybridization was performed over-
night under the same conditions. For RNA in situ hybridization
on sections, embryos were collected, fixed, incubated overnight
in 30% sucrose, embedded in cryomatrix, and 10-µm sections
were applied to Probe-on Plus slides (Fisher Scientific). De-
frosted sections were hybridized overnight with DIG-labeled
probes in a medium containing 50% formamide, 10% dextran
sulphate, 1 mg/mL yeast tRNA, 0.02% BSA, 0.02% Ficoll, and
0.02% PVP.
Embryos and sectioned tissues were washed successively in
50% formamide, 1× SSC, 0.1% Tween-20 at 70°C for 70 min,
and MABT at pH 7.5 (100 mMmaleic acid; 150 mMNaCl; 0.1%
Tween-20) at room temperature for 1 h and blocked in PBS
containing 20% inactivated fetal calf serum for 90 min. Anti-
DIG antibody (1:2500) was applied overnight in the same
solution at room temperature. Tissues were washed thoroughly
in MABT for 2 h, rinsed with NTMT (100 mM NaCl; 100 mM
Tris-HCl at pH 9.5; 50 mM MgCl2; 1% Tween-20) for 1 h,
stained in a solution containing 350 µg/mL NBT, 175 µg/mL
BCIP, rinsed in PBS, and fixed in 4% paraformaldehyde. The
Arx cRNA probe used was transcribed from a PCR-generated
fragment encompassing the 8–1168-bp region of Arx full-length
cDNA. The -galactosidase cRNA PCR-generated probe
contains the 675–1140-bp portion of the -galactosidase
cDNA.
Immunohistochemistry
Tissues were fixed in 4% paraformaldehyde, embedded in par-
affin and 6-µm sections were applied to Probe-on Plus slides
(Fisher Scientific). Deparaffinized and rehydrated sections were
permeabilized in 0.2% Triton X-100 for 5 min and blocked in
PBS containing 10% inactivated fetal calf serum for 90 min.
Primary antibodies were diluted in the same medium, applied
on sections, and incubated overnight at 4°C. Slides were washed
in PBS and incubated for 90 min with the appropriate secondary
antibody diluted in PBS containing 10% inactivated fetal calf
serum. Slides were washed in PBS, mounted with DAPI, and
viewed by fluorescent microscopy. Sections that had been sub-
jected to in situ hybridization were washed in PBS, blocked, and
incubated with primary antibodies as described above.
The primary antibodies used in these assays were as follows:
mouse monoclonal anti-insulin diluted 1/1000 (Sigma); mouse
monoclonal anti-glucagon diluted 1/1000 (Sigma); guinea-pig
anti-insulin diluted 1/1000 (Sigma); guinea-pig anti-glucagon di-
luted 1/1000 (Sigma); rabbit anti-somatostatin diluted 1/600
(Dako); rabbit anti-PP diluted 1/200 (Dako); rabbit anti--galac-
tosidase diluted 1/300 (Molecular Probes); mouse anti--galac-
tosidase diluted 1/5000 (Promega); rabbit anti-Nkx6.1 diluted
1/3000; rabbit anti-Pdx1 diluted 1/2000 [kindly provided by C.
Wright (Vanderbilt University, Nashville, TN)]; rabbit anti-Isl1
diluted 1/2000 [kindly provided by T. Jessell (Columbia Univer-
sity, New York)]; rabbit anti-Hb9 diluted 1/10000 (kindly pro-
vided by T. Jessell); rabbit anti-Nkx2.2 diluted 1/1000 (kindly
provided by T. Jessell); rabbit anti-Pax6 diluted 1/500 [kindly
provided by S. Saule (UMR 146, Orsay, France)]; rabbit anti-
Ngn3 diluted 1/2000 [kindly provided by M. German (Diabetes
Center, San Francisco, CA)]; and rabbit anti-Arx diluted 1/4500.
The secondary antibodies (Molecular Probes, dilution 1/1000)
used for immunofluorescence were as follows: 594-alexa anti-
mouse; 488-alexa anti-mouse; 594-alexa anti-rabbit; 488-alexa
anti-rabbit; 594-alexa anti-guinea pig; and 488-alexa anti-guinea
pig.
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Glucose levels
Glucose levels were determined with the One Touch Glucose
monitoring kit (Johnson & Johnson) using 15 µL of peripheral
blood from 0.5-, 1-, and 2-day-old mice. Blood glucose levels are
represented as an average ± standard deviation.
RNA isolation and cDNA synthesis
RNA was isolated by lysing tissues in guanidinium thiocya-
nate/phenol buffer (Trizol; Invitrogen) according to the manu-
facturer’s instructions. After resuspension in RNase-free water,
ethanol precipitation, and wash in 70% ethanol, the total RNA
was diluted in RNase-free water to 2 µg/µL. cDNA synthesis
was performed with the superscript single-stranded cDNA syn-
thesis kit (Invitrogen) according to manufacturer’s instructions.
Briefly, 10 µg of total RNA were denatured at 70°C for 10 min,
quickly chilled on ice, and subjected to cDNA synthesis at 45°C
for 1 h.
RT–PCR and multiplex RT–PCR reactions
RT–PCR were carried out in 50-µL reactions using 0.5 µL of
the diluted cDNA product as template with 47 µL of PCR mix
(Genecraft); 10 pM of each primer and 2.5 U of Taq polymerase
(Genecraft). Multiplex RT–PCR reactions were performed
strictly following the protocol described by Jensen et al. (1996)
by use of primers derived from insulin, glucagon, somatostatin,
-tubulin (data not shown), TATA-box-binding protein, Arx,
and Pax4 genes. Previously unmentioned primers and multiplex
RT–PCR conditions were as follows: Arx 5Oligo (CAG
CATTTGGCAGGCTCT) and 3oligo (AGGATGTTGAGCT
GCGTGAG), producing a 178-bp PCR product (26 cycles), and
Pax4 5Oligo (ACCTCATCCCAGGCCTATCT) and 3oligo
(AGGCCTCTTATGGCCAGTTT), producing a 220-bp PCR
product (25 cycles). Reaction products labeled with [-32P]dCTP
(Amersham) were separated on 6% polyacrylamide gels, dried,
and exposed overnight to a phosphorimage storage screen.
Screens were subsequently scanned by a Molecular Dynamics
PhosphorImager Series 400, and band intensities were calcu-
lated using the Imagequant software with rectangle mode/local
background/volume integration. All amplicons were measured
against the internal standards TATA-box-binding protein.
Preparation of polyclonal antibodies
Rabbits were injected with a mixture of three peptides corre-
sponding to amino acids 2–16, 167–181, and 314–329 of Arx
coupled to keyhole limpet hemocyanin (Eurogentec).
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